Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263270 | 0.76 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL969704 | 0.74 | SHBG (0.56) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL7507782 | 0.74 | TP53 (0.41) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL892135 | 0.74 | SHBG (0.56) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL1193182 | 0.74 | SHBG (0.56) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL9204742 | 0.72 | — | — | |
| SCHEMBL4379254 | 0.72 | EPHX1 (0.62) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL635367 | 0.72 | EPHX1 (1.00) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL9717438 | 0.72 | EPHX1 (0.62) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5720721 | 0.72 | EPHX1 (0.37) | EPHX1TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| CN-101914040-A | Acyloxyalkyl carbamate prodrugs, synthetic method and purposes | XENOPORT INC | 2010-12-15 | — | — | CN | disclosed |
| CN-1860101-B | Acyloxyalkyl carbamate prodrugs, synthesis methods and uses | XENOPORT INC | 2010-10-27 | — | — | CN | disclosed |
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2007-12-27 | — | — | US | disclosed |
| CN-101001612-A | Controlled release dosage forms for gamma aminobutyric acid receptor agonists | IMPAX LABORATORIES INC (US) | 2007-07-18 | — | — | CN | disclosed |
| CN-1860101-A | Acyloxyalkyl carbamate prodrugs, synthesis methods and uses | XENOPORT INC (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1696959-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1401423-A4 | METHOD OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND NOCTURNAL ACID BREAKTHROUGH | DEPOMED DEV LTD (BM) | 2006-08-16 | — | — | EP | disclosed |
| US-20050215521-A1 | Modafinil combination therapy for improving sleep quality | SEPRACOR INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063248-A1 | MODAFINIL COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1401423-A1 | METHOD OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND NOCTURNAL ACID BREAKTHROUGH | Depomed Development, Ltd (GB) | 2004-03-31 | — | — | EP | disclosed |
| CN-1117560-C | Reflux inhibitors | ASTRA AB (SE) | 2003-08-13 | — | — | CN | disclosed |
| US-20030031711-A1 | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough | ASSERTIO THERAPEUTICS, INC. | 2003-02-13 | — | — | US | disclosed |
| WO-2002096404-A1 | METHOD OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND NOCTURNAL ACID BREAKTHROUGH | DEPOMED DEVELOPMENT LTD (GB) | 2002-12-05 | — | — | WO | disclosed |
| CN-1237105-A | Reflux inhibitors | ASTRA AB (SE) | 1999-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | EPHX1 3265/4885TP53 4870/4885KDM4E 582/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | EPHX1 3402/4885TP53 4838/4885KDM4E 634/4885 |
| US-20050215521-A1 | Modafinil combination therapy for improving sleep quality | HCRTR2, HCRTR1, MTNR1A | EPHX1 2042/4885TP53 4884/4885KDM4E 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.